78P - Population based mammographic screening in India: Analysis from community outreach cancer screening program

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Breast Cancer, Early Stage
Cancer Aetiology, Epidemiology, Prevention
Presenter shyam Bisht
Citation Annals of Oncology (2016) 27 (suppl_9): ix19-ix29. 10.1093/annonc/mdw575
Authors S.S. Bisht1, T. Kataria1, D. Gupta1, A. Abhishek1, S. Goyal1, T. Basu1, K. Narang1, M. Tayal1, S. Banarjee1, J. Arora2, S. Razdan3
  • 1Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, 122001 - Gurgaon/IN
  • 2Radiology, Medanta Cancer Institute, Medanta The Medicity, 122001 - Gurgaon/IN
  • 3Breast Surgery, Medanta Cancer Institute, Medanta The Medicity, 122001 - Gurgaon/IN

Abstract

Background

Breast cancer is increasing in the developing countries. The risk factors are not easily modifiable therefore secondary prevention with screening is the way forward. Mammography (MG) remains the main modality of screening with significant decrease in breast cancer mortality. Most of this evidence is from developed countries. Demographics and tumor biology of Indian breast cancer patient is different from western world. Thus similar benefit of screening MG in India is debated. Furthermore data on MG in Indian population is not available.

Methods

Breast cancer screening through mobile MG van (Siemens) was inducted in 2012 as a part of community outreach program (Health camps) at our hospital. Asymptomatic females above the age of 40 years, who attended the health camps underwent bilateral breast (craniocaudal and mediolateral view) screening MG after consultation with oncologist. Females younger than 40 years with family history of breast cancer also underwent the test after the risk/benefit discussion. All MG were reported by in-house radiologist and cases were informed for any further action. MG data of 4106 cases from 169 camps conducted in urban and suburban region of north and central India between Feburary 2012-May 2016 were selected. Cases with history of breast cancer and unilateral MG were excluded (n = 104). 4002 patients were selected. Patient were segregated in age bins:

Results

BIRADS

N

%

Mean Age

SD

<40YRS (%)

40-49 (%)

50-59 (%)

60-69 (%)

70+ (%)

0

802

20

47

7.3

8.45

60.45

23.23

6.52

1.33

1

2239

55.9

51.9

8.8

3.4

40

35.4

16.95

4.25

2

437

10.9

55.1

9.8

1.6

29.2

34.05

26.15

9

3

421

10.5

50.3

8.5

5.22

45.13

34.44

12.58

2.61

4

56

1.39

49.9

9.7

5.35

46.4

33.92

7.14

7.14

5

15

0.37

52.8

8.18

6.67

26.67

40

26.67

0

Fault-Technical

32

0.8

TOTAL

4002

100

51.2

9

4.35

42.86

33.16

15.53

4

Conclusions

The average age of screened population was 51 years with majority of population (76%) in the 40-59 years. 20% of population was above 60 years. The incidence of BIRADS 0-2 was 87% . BIRADS 3 was 10.5% in overall population. BIRADS 4-5 constitutes 1.76%.

Clinical trial indentification

na

Legal entity responsible for the study

Medanta The Medicity

Funding

N/A

Disclosure

All authors have declared no conflicts of interest.